Pacira Pharmaceuticals (PCRX) Receives a Buy from Leerink Partners

By Carrie Williams

Leerink Partners analyst Ami Fadia maintained a Buy rating on Pacira Pharmaceuticals (PCRXResearch Report) today and set a price target of $45.00. The company’s shares closed last Thursday at $42.35.

According to TipRanks.com, Fadia is a 2-star analyst with an average return of -0.1% and a 43.5% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Osmotica Pharmaceuticals, Jazz Pharmaceuticals, and Endo International.

Currently, the analyst consensus on Pacira Pharmaceuticals is a Strong Buy with an average price target of $54.85, representing a 24.2% upside. In a report issued on April 27, Wedbush also reiterated a Buy rating on the stock with a $85.00 price target.

See today’s analyst top recommended stocks >>

Based on Pacira Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $122 million and GAAP net loss of $4.89 million. In comparison, last year the company earned revenue of $95.11 million and had a net profit of $8.29 million.

Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PCRX in relation to earlier this year. Most recently, in March 2020, John Phd Longenecker, a Director at PCRX bought 3,736 shares for a total of $6,015.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.